Carl Zeiss Meditec AG (MEX:AFXN) Research & Development: MXN7,008 Mil (TTM As of Dec. 2025)


MEX:AFXN Carl Zeiss Meditec AG MEX:AFXN
68 GF Score
Price MXN3,258.20
GF Value MXN8,900.18
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Research & Development?

Carl Zeiss Meditec AG MEX:AFXN 68 Research & Development is MXN7,008 Mil as of Dec. 2025. GuruFocus rates MEX:AFXN with a GF Score™ of 68/100 and a GF Value™ of MXN8,900.18. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Carl Zeiss Meditec AG's Research & Development for the three months ended in Dec. 2025 was MXN1,592 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was MXN7,008 Mil.

Carl Zeiss Meditec AG  (MEX:AFXN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Carl Zeiss Meditec AG Research & Development Related Terms

Carl Zeiss Meditec AG Research & Development Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Research & Development Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,613.81 5,802.78 6,493.10 7,497.81 7,024.95

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,692.48 1,671.78 1,768.40 1,975.99 1,591.84
MEX:AFXN
68GF Score
Carl Zeiss Meditec AG MEX:AFXN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN7,008 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN7,008 Mil mean?
Carl Zeiss Meditec AG (MEX:AFXN) has a Research & Development of MXN7,008 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Research & Development too high?
Carl Zeiss Meditec AG's current Research & Development is MXN7,008 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Research & Development compare to ISRG and BDX?
Carl Zeiss Meditec AG's Research & Development of MXN7,008 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Research & Development is MXN7,008 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (MEX:AFXN) has a current Research & Development of MXN7,008 Mil. The stock's GF Value™ is MXN8,900.18, compared to a current price of MXN3,258.20 — trading 63.4% below its estimated fair value. The current Research & Development is MXN7,008 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Carl Zeiss Meditec AG (MEX:AFXN), the current Research & Development is MXN7,008 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (MEX:AFXN) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of MXN3,258.20 is trading 63.4% below its estimated GF Value™ of MXN8,900.18.

Key valuation signals for MEX:AFXN:

  • Research & Development: MXN7,008 Mil
  • GF Value™: MXN8,900.18 vs. price of MXN3,258.20 (63.4% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:AFXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
68GF Score

Get the complete analysis for MEX:AFXN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,258.20
Price
MXN8,900.18
GF Value